Talaris Therapeutics, Inc.
TALS

$116.44 M
Marketcap
$2.72
Share price
Country
$-0.02
Change (1 day)
$3.29
Year High
$0.89
Year Low
Categories

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

marketcap

P/B ratio for Talaris Therapeutics, Inc. (TALS)

P/B ratio as of 2022: 0.02

According to Talaris Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.02. At the end of 2021 the company had a P/B ratio of 0.18.

P/B ratio history for Talaris Therapeutics, Inc. from 2019 to 2022

P/B ratio at the end of each year

Year P/B ratio
2022 0.02
2021 0.18
2020 0.07
2019 -0.61